Telomir Pharmaceuticals, Inc. (TELO) is a Miami-based clinical-stage biotechnology company developing oral small-molecule therapies aimed at epigenetic and metabolic drivers of cancer and age-related disease. Its lead candidate, Telomir-Zn, has FDA Investigational New Drug clearance for a Phase 1/2 study in advanced or metastatic triple-negative breast cancer. In the first minutes of trading on Thursday, Nov. 19, the stock rose 10.57% to $0.46495, compared with the prior session's close of $0.4205 — a clear move higher. No new company release explained the advance; the rebound followed a steep multi-week decline and arrived alongside a firmer broader tape.
On Nov. 18, Telomir disclosed in a regulatory filing and press release that it had selected Linical, a global contract research organization with oncology experience, to run its FDA-cleared Phase 1/2 trial of Telomir-Zn in triple-negative breast cancer. The company said a master services agreement and work order are executed, with clinical initiation targeted for the first quarter of 2027. That is a genuine operational milestone for a company this size, but it is a logistics step rather than a data readout — and notably, shares slipped 0.6% on the day it was published. The disclosure therefore functions as a supportive backdrop for buyers returning to the name, not the trigger for Thursday's gain.
The price action is most consistent with a technical bounce. The stock fell in seven of the eight sessions before Thursday, including declines of 17.1% on Nov. 10, 15.9% on Nov. 12 and 12.0% on Nov. 17, when it touched $0.401. After a drawdown of that magnitude, modest buying interest can produce an outsized percentage gain. Liquidity amplifies the effect: with a float turning over roughly 100,000 shares a day and quoted spreads that have been wide, small orders can move the tape several cents. Short interest of about 750,000 shares as of the Oct. 30 settlement — several sessions' worth of typical turnover — also creates potential for covering to accelerate any rebound. Neither factor is confirmed as the cause, but both are consistent with the size of the move.
Early volume was light relative to the recent daily average, suggesting the gain reflects a thin order book rather than heavy accumulation. The move diverged sharply from its sector: biotech broadly added only about half a percent, small caps were roughly flat, and large-cap technology led the tape with the Nasdaq-100 up nearly 2%. Even after Thursday's advance, the stock trades far below its 50-day and 200-day moving averages and remains a sub-$1 issue, with the $0.50 area the nearest reference point overhead.
On a scale where 0 means no meaningful news and a move that is normal for the stock, and 100 means transformative news and an extreme, rare move, this event scores 38 out of 100. The verified news is modest — a contract research organization selection that sets up a trial expected to begin in the first quarter of 2027, meaningful for a company of this size but well short of a clinical result. The price move is unusual but not unprecedented: roughly 3.4 times the typical daily swing, with only four larger moves in the past 60 sessions. A moderate catalyst combined with a moderately rare move lands the score in the high 30s.
The next hard milestone is clinical initiation for the triple-negative breast cancer study, guided for the first quarter of 2027, followed by enrollment updates. Telomir's third-quarter report showed a net loss of $0.705 million, narrower than a year earlier, and the company bolstered its balance sheet with a $5.6 million private placement in October — figures investors will weigh against the cost of running a Phase 1/2 program. Because there is no product revenue, financing needs and potential share issuance remain the central risk, alongside the possibility that trial timelines slip. Trading below $1 also leaves the stock exposed to minimum-bid compliance scrutiny and continued volatility around sparse news flow.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions appear in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so investors can compare approaches side by side. Reviewing the current leaders is a practical way to see how automated strategies are positioned in this market.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TELO declined for three days, in 147 of 174 cases, the price declined further within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for TELO entered a downward trend on November 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where TELO advanced for three days, in 92 of 118 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
TELO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.702) is normal, around the industry mean (3.596). P/E Ratio (-0.640) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.004) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TELO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TELO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology